In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Optimal timing for cardiovascular magnetic resonance after ST-segment elevation myocardial infarction for effective risk stratification
Sub-topic : Late Gadolinium Enhancement and Viability
Session type : Moderated Posters
Authors : A G Pavon (Lausanne,CH), G Pontone (Milan,IT), R Symons (Leuven,BE), M Francone (Rome,IT), J Zalewski (Krakow,PL), A Barison (Pisa,IT), GD Aquaro (Pisa,IT), G Muscogiuri (Milan,IT), O Muller (Lausanne,CH), A Baggiano (Leuven,BE), D Andreini (Milan,IT), PG Camici (Milan,IT), J Schwitter (Lausanne,CH), J Bogaert (Leuven,BE), PG Masci (Lausanne,CH)
Background: In ST-segment-elevation myocardial infarction (STEMI), cardiovascular magnetic resonance (CMR) holds the potentiality to improve risk stratification beyond Thrombolysis-in-Myocardial-Infarction (TIMI) risk-score. Nevertheless, the optimal timing for CMR after STEMI remains poorly defined. Objectives: Comparing prognostic performance of three different stratification strategies according to the timing of CMR after STEMI. Methods: The population of this prospective registry-based study included 511 reperfused STEMI patients. All patients underwent post-reperfusion (median:4-days post-STEMI) and follow-up (median:4.8-months post-STEMI) CMR. Left ventricular (LV) volumes, function, infarct-size and microvascular-obstruction extent (MVO) were quantified. Primary end-point was a composite of all-death and heart failure (HF) hospitalization.Three multivariate models were developed including TIMI risk-score plus early post-STEMI (early-CMR) or follow-up CMR (deferred-CMR) or both CMRs parameters along with adverse LV remodeling (paired-CMRs). Results: During a median follow-up of 8.5 years, primary end-point occurred in 85 patients (23 deaths; 38 HF hospitalization). Early-CMR, deferred-CMR and paired-CMRs demonstrated similar predictive value for primary end-point (C-statistic: 0.726, 0.728, 0.738, respectively; P=0.663). However, early-CMR enabled to correctly estimate poor outcome in 4 of 7 patients (56%) developing primary end-point between early- and deferred-CMR. Conclusions: In STEMI, early-CMR should be considered the preferred strategy for timely effective risk stratification.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease